127例铂类抗癌药物不良反应报告回顾性分析  

The retrospective analysis of 127 cases of adverse drug reactions reports induced by platinum anticancer drugs

作　　者：金星[1] 吴文清[1] 伍延婷 

机构地区：[1]鄂东医疗集团黄石市中心医院,湖北黄石435001

出　　处：《安徽医药》2017年第5期957-959,共3页Anhui Medical and Pharmaceutical Journal

摘　　要：目的探讨铂类药物不良反应(ADR)发生的特点及规律。方法对该院2010—2015年填报的127例铂类药物ADR报告进行统计分析。结果 127例ADR报告中顺铂72例(56.69%)和奥沙利铂31例(24.41%)最多见,>44~≤60岁的中年病人所占比例最高71例(55.91%),联合用药73例(57.48%);临床表现以胃肠系统损害和血液系统损害最常见,其中胃肠系统损害绝大多数出现于用药后当日,而血液系统损害主要发生在用药后1~10 d。结论临床应加强铂类药物ADR监测工作,保障肿瘤病人用药安全。Objective To investigate the characteristics and regularity of adverse drug reaction（ ADR） induced by platinum anticancer drugs. Methods 127 ADR cases induced by platinum anticancer drugs in our hospital from 2010 to 2015 were analyzed retrospective-ly. Results The most common drugs in these ADR cases were cisplatin （56. 69% ） and oxaliplatin （24. 41% ）. The patients aged from 〉44 -≤60 years accounted for the highest proportion （55. 91% ）. Combined use of drugs occurred in 73 cases （57. 48% ）. The major clinical manifestations of ADR were the damages of gastrointestinal system and blood system. Most of the gastrointestinal system damage occurred in the day after the drug treatment, and blood system damage occurred mainly in 1 to 10 d after treatment. Conclusion ADR monitoring of platinum anticancer drugs should be strengthened to protect the safety of drug use in cancer patients.

关 键 词：铂类药物 不良反应 安全用药 

分 类 号：R979.1[医药卫生—药品]